Free Trial
NASDAQ:BIAF

bioAffinity Technologies Q4 2024 Earnings Report

bioAffinity Technologies logo
$0.50 -0.01 (-2.54%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$0.52 +0.02 (+3.81%)
As of 04/25/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

bioAffinity Technologies EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.14
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

bioAffinity Technologies Revenue Results

Actual Revenue
$2.20 million
Expected Revenue
$2.42 million
Beat/Miss
Missed by -$216.00 thousand
YoY Revenue Growth
N/A

bioAffinity Technologies Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 31, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

bioAffinity Technologies' next earnings date is estimated for Tuesday, May 13, 2025, based on past reporting schedules.

bioAffinity Technologies Earnings Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
See More bioAffinity Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like bioAffinity Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bioAffinity Technologies and other key companies, straight to your email.

About bioAffinity Technologies

bioAffinity Technologies (NASDAQ:BIAF), a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

View bioAffinity Technologies Profile

More Earnings Resources from MarketBeat